Royal Bank of Canada Raises Stock Position in Ralliant Corporation $RAL

Royal Bank of Canada raised its position in Ralliant Corporation (NYSE:RAL) by 175.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,251 shares of the company’s stock after purchasing an additional 32,024 shares during the quarter. Royal Bank of Canada’s holdings in Ralliant were worth $2,091,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Danske Bank A S purchased a new stake in shares of Ralliant during the 4th quarter valued at approximately $25,000. Allworth Financial LP grew its position in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares during the period. Palisade Asset Management LLC purchased a new position in Ralliant in the third quarter worth approximately $26,000. Rothschild Investment LLC increased its stake in Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after acquiring an additional 303 shares during the last quarter. Finally, BOKF NA acquired a new stake in Ralliant during the third quarter worth $29,000.

Ralliant Trading Down 0.4%

RAL opened at $72.03 on Tuesday. The business has a fifty day moving average price of $68.82 and a 200 day moving average price of $55.58. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41. The stock has a market capitalization of $7.97 billion, a price-to-earnings ratio of -6.64, a PEG ratio of 2.69 and a beta of 1.61.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Sell-side analysts expect that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s payout ratio is currently -1.84%.

Analyst Upgrades and Downgrades

RAL has been the topic of several recent analyst reports. Wall Street Zen lowered Ralliant from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 11th. Morgan Stanley boosted their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a research report on Wednesday, May 27th. Citigroup increased their target price on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.70.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.